Clinical pipeline Target radiopharmaceuticals for rare cancers present in late-stage preclinical or early clinical development with potential for strategic partnerships or licensing deals, particularly EBTATE and EBRGD with NIH licenses and ongoing trials.

Rare cancer focus Specialization in gastroenteropancreatic neuroendocrine tumors, Hürthle cell thyroid tumors, glioblastoma, and NSCLC positions the company to pursue niche collaborations with oncology focused CROs, biotech firms, and radiopharmaceutical manufacturers.

Strategic partnerships History of collaborations and licenses (NIH, Brookline Capital Markets, Memorial Sloan Kettering trial sites) suggests a roadmap for co-development, manufacturing alliances, and capital market partnerships to accelerate trials and commercialization.

Operational readiness Small team size combined with active partnerships indicates outsourcing opportunities for clinical operations, regulatory affairs, and manufacturing scale-up, making potential suppliers and service providers viable sales targets.

Market traction signals Recent conference activity and leadership appointments (CMO hire, SVP of Clinical Development) signal momentum and greater likelihood of clinical data milestones, creating timely selling windows for radiopharmaceutical vendors, imaging agents, and contract manufacturers.